CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
https://policybase.cma.ca/link/policy11125

POLICY TYPE
Parliamentary submission

DATE
2014-03-26

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE  Parliamentary submission
DATE  2017-04-06
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone

https://policybase.cma.ca/link/policy11847

POLICY TYPE Response to consultation
DATE 2016-03-19
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Response: Consultation on the Prescription Drug List: Naloxone

Health Canada - Prescription Drug Stakes Committee

March 19, 2016
Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/link/policy11535

POLICY TYPE
Policy document

DATE
2015-05-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE: Response to consultation
DATE: 2018-12-04
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE  Response to consultation
DATE  2018-08-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-07-18</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

Documents

![Image](cma政策咨询-限制营销和广告化草本药物)
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy11035

POLICY TYPE  Parliamentary submission
DATE  2013-11-27
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE  Response to consultation
DATE  2017-11-7
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image: CMA Submission: Non-Prescription Availability of Low-Dose Codeine Products]

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
Open letter to Ontario Minister of Health about the newly proposed “Consumption and Treatment Services” model

https://policybase.cma.ca/link/policyl3932

POLICY TYPE
Policy endorsement

DATE
2018-10-31

TOPICS
Population health, health equity, public health

Documents
Proposed amendments to the marihuana for medical purposes regulations
https://policybase.cma.ca/link/policy11293

POLICY TYPE
Response to consultation

DATE
2014-07-11

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations
https://policybase.cma.ca/link/policy11114

POLICY TYPE  Response to consultation
DATE  2014-03-17
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE
Parliamentary submission

DATE
2016-10-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

https://policybase.cma.ca/link/policy13931

POLICY TYPE
Policy endorsement

DATE
2018-08-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents